MAPT and Parkinson disease: Assays for other phosphorylation targets of p-tau are also emerging: p-tau217 assays have recently been shown to be more sensitive than p-tau181 to PET-amyloid positivity and progression to Alzheimer’s dementia in patients with MCI.122,123 Plasma p-tau217 levels are also predictive of abnormal tau-PET and β-amyloid CSF status in dementia with Lewy bodies and PD dementia124 but these have not yet been applied in earlier stages of PD and could be examined in future work.